Sign in to view content

Fluctuations in Central Foveal Thickness and Vision Outcomes With AntiVEGF Therapy for Neovascular Age-Related Macular Degeneration

Veeral S. Sheth, MD, MBA, FASRS, FACS

Video
Published 2020

Related

Apples and Oranges: "Real-World" Outcomes Differ From Clinical Trial Outcomes Because "Real-World" Patients Differ From Clinical Trial Patients
Franco M. Recchia, MD
Annual Meeting Talks
2021
Anti-VEGF treatment switch in DME and nAMD: a comparison of aflibercept versus ranibizumab after a single-dose switch
Estephania Feria, MD
On Demand Cases, Courses, and Papers
2019
Anti-VEGF treatment switch in DME and nAMD: a comparison of aflibercept versus ranibizumab after a single-dose switch
Estephania Feria, MD
On Demand Cases, Courses, and Papers
2019

Category: Age-Related Macular Degeneration

See more